Overview

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the safety and tolerability of Phenlarmide tablets in patients with Parkinson's disease in the early and middle stages. 2. To evaluate the pharmacokinetics of Phenlarmide tablets in patients with Parkinson's disease. 3. To explore the efficacy of Phenlarmide tablets in the treatment of early and mid-term Parkinson's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Collaborator:
Xuanwu Hospital, Beijing